北京植德律师事务所 关于 哈尔滨誉衡药业股份有限公司 2024 年限制性股票激励计划之 首次授予部分第一个限售期解除限售事宜的 法律意见书 植德(证)字[2024]002-6 号 二〇二五年四月 北京植德律师事务所 Merits & Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编: 100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel) : 010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于哈尔滨誉衡药业股份有限公司 2024 年限制性股票激励计划之 首次授予部分第一个限售期解除限售事宜的 法律意见书 植德(证)字[2024]002-6 号 致:哈尔滨誉衡药业股份有限公司 根据北京植德律师事务所(以下简称"本所")与哈尔滨誉衡药业股份有限 公司(以下简称"公司")签署 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 551,255,672.12, a decrease of 7.06% compared to CNY 593,133,301.68 in the same period last year[3] - Net profit attributable to shareholders increased by 15.24% to CNY 60,252,267.26, up from CNY 52,282,909.59 year-on-year[3] - The net profit after deducting non-recurring gains and losses rose by 54.74% to CNY 49,733,030.46, compared to CNY 32,140,693.96 in the previous year[3] - The company reported total operating revenue of ¥551,255,672.12 for the current period, a decrease from ¥593,133,301.68 in the previous period, reflecting a decline of approximately 7.1%[27] - The total profit for the current period is CNY 68,950,223.62, compared to CNY 68,413,553.70 in the previous period, reflecting a slight increase of 0.8%[28] - Operating profit for the current period is CNY 69,069,634.07, slightly up from CNY 68,449,052.90 in the previous period[28] - The net profit for the current period is CNY 61,931,584.62, an increase of 11.6% compared to CNY 55,761,035.49 in the previous period[28] - Basic earnings per share increased to CNY 0.0274 from CNY 0.0235, reflecting a growth of 16.6%[29] Cash Flow and Assets - The net cash flow from operating activities decreased by 33.14% to CNY 106,474,494.15, down from CNY 159,239,649.03 in the same period last year[3] - The cash flow from operating activities for the current period is CNY 106,474,494.15, down 33.1% from CNY 159,239,649.03 in the previous period[31] - The net cash flow from investment activities was negative CNY 112,950,739.92, a significant increase in outflow compared to negative CNY 4,756,664.99 in the previous year[13] - The company's cash and cash equivalents at the end of the reporting period amounted to ¥461,761,822.17, down from ¥481,962,600.35 at the beginning of the period, a decrease of approximately 4.5%[24] - The company's total assets at the end of the reporting period were CNY 2,878,651,000.44, reflecting a 1.90% increase from CNY 2,825,112,612.64 at the end of the previous year[3] - The company's total liabilities rose to ¥920,357,347.36 from ¥852,260,332.70, an increase of approximately 8.0%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 87,994[15] - The top 10 shareholders hold a combined 18.12% of the total shares, with the largest shareholder, Shen Zhenyu, owning 4.92%[15] - Shen Zhenyu holds 110,490,000 shares, with 75% of these being locked-up shares[17] - The company repurchased a total of 32,307,224 shares from March 10 to March 13, 2025, accounting for 1.42% of the total share capital[18] - The highest transaction price during the repurchase was 2.51 RMB per share, and the total funds used for the repurchase amounted to 79,994,101.62 RMB[18] - The company has completed the repurchase and cancellation of 1,653,000 shares of restricted stock from eight departed incentive plan participants[21] Legal and Regulatory Matters - The company is involved in an ongoing lawsuit regarding a 42.12% equity transfer of Guangzhou Yuheng Biotechnology Co., Ltd., with a court ruling in favor of the company[20] - The company completed a board restructuring on February 6, 2025, during the first extraordinary shareholders' meeting[17] Research and Development - Research and development expenses increased to CNY 15,046,259.26 from CNY 14,704,935.33, representing a growth of 2.3%[28] - The company has received approval for its potassium chloride oral solution, enhancing its product offerings in the potassium supplementation market[22] - The company has not disclosed any new product or technology developments in the current reporting period[15] Market and Future Outlook - There are no indications of market expansion or mergers and acquisitions mentioned in the report[15] - The company has not provided specific future guidance or performance outlook in the current report[15] Financial Expenses and Investments - Financial expenses decreased by 82.43% to CNY 232,729.85, primarily due to a significant reduction in bank loans[10] - The company recorded a fair value change gain of CNY 3,559,330.01, a 131.21% increase compared to the previous year's loss[10] - The company’s long-term equity investments were valued at ¥68,143,581.25, slightly down from ¥68,292,921.95, indicating a minor decrease of about 0.2%[25] - The company’s inventory decreased to ¥185,855,538.43 from ¥188,671,540.43, reflecting a decline of approximately 1.4%[25]

Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, reached 183.31 million RMB, a year-on-year increase of 243.42%[4] - The weighted average return on equity improved from 7.26% to 12.89%[4] - The net cash flow from operating activities was 411 million RMB, an increase of nearly 50% year-on-year[5] - The company's operating revenue for 2024 was CNY 2,440,732,030.17, a decrease of 7.06% compared to CNY 2,626,039,306.71 in 2023[28] - Net profit attributable to shareholders for 2024 reached CNY 232,759,457.12, representing a significant increase of 93.43% from CNY 120,334,186.37 in 2023[28] - The cash flow from operating activities for 2024 was CNY 410,935,803.11, up by 49.88% compared to CNY 274,175,284.57 in 2023[28] - The basic earnings per share for 2024 was CNY 0.1059, an increase of 93.60% from CNY 0.0547 in 2023[28] - The net assets attributable to shareholders increased by 17.39% to CNY 1,950,697,287.55 at the end of 2024, compared to CNY 1,661,773,347.48 at the end of 2023[28] - The company achieved a total revenue of 2.44 billion yuan, with a net profit of 233 million yuan, representing a year-on-year growth of 93.43%[58] Sales and Market Performance - Sales of the injectable multivitamin product increased by over 40%, while sales of the An Nao Wan/Pian product surged by over 90%[5] - The company achieved a sales growth of over 90% for its core product, An Nao Wan/Pill, which is now covered by over 3,900 hospitals and primary medical institutions[49] - The potassium chloride sustained-release tablet (Bu Da Xiu) holds a market share of 55.37% in urban retail pharmacies and 29.41% in public hospitals, ranking first and second in their respective segments[50] - The injection of multiple vitamins maintains a market share of over 80% and has been selected in multiple centralized procurement programs[51] - The company’s injection of deer melon peptide has a market share of 56.46% in public hospitals, leading its segment[51] - The company’s Ginkgo biloba injection has a stable market position with a 55.77% market share in public hospitals[52] Research and Development - The company has over 20 projects under research and has submitted more than 10 listing applications to the CDE, with 4 products approved[7] - The company launched five new research projects in key areas such as cardiovascular and orthopedic fields, with over 20 projects currently under development[59] - R&D investment increased by 8.80% to ¥97,008,551.90 in 2024, compared to ¥89,158,520.74 in 2023[74] - The number of R&D personnel rose by 13.33% to 102 in 2024, up from 90 in 2023[74] - The proportion of R&D investment to operating revenue increased to 3.97% in 2024 from 3.40% in 2023, a change of 0.57%[74] Financial Management and Cost Control - The company reduced financial expenses by 32.38 million RMB through early repayment of bank loans and improved capital efficiency[6] - Management expenses, excluding equity incentive costs, decreased by 18.29% year-on-year[6] - The asset-liability ratio decreased to 30%, the lowest in 10 years, indicating improved financial structure[6] - The company reported a significant reduction in financial expenses, decreasing by 103.41% to -¥1,067,714.14 due to reduced interest costs from loan repayments[71] - Sales expenses decreased by 25.82% to ¥792,647,941.82, while management expenses decreased by 4.85% to ¥166,704,878.22[71] Corporate Governance and Compliance - The company aims to enhance compliance and governance mechanisms, including the cancellation of the supervisory board and strengthening the audit committee's role[8] - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and regulations, and maintaining the integrity of shareholder meetings[108] - The company maintains a strict internal audit system, with an audit committee composed of a majority of independent directors[114] - The company has a dedicated investor relations management system to enhance communication with investors[113] - The company is in compliance with the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[138] Industry Outlook and Challenges - The pharmaceutical manufacturing industry faced challenges in 2024, with a total revenue of CNY 25,298.5 billion, remaining flat compared to 2023[38] - The company experienced a decline in total revenue due to ongoing price reductions in the pharmaceutical sector and increased competition[38] - The pharmaceutical industry in China is expected to maintain steady growth due to increasing demand driven by an aging population, rising income levels, and enhanced healthcare awareness[39] - The company faces industry policy risks that could impact sales and pricing, and it plans to adapt its business model accordingly[99] - The company faces significant risks in drug development due to increasing regulatory requirements and potential funding increases, which may lead to higher failure rates in drug projects[100] Environmental and Social Responsibility - The company is committed to improving its environmental protection and safety management systems to meet higher regulatory demands and fulfill corporate social responsibilities[103] - The company is classified as a key pollutant discharge unit in Harbin for 2024, adhering to environmental protection laws and standards[164] - The company has obtained pollution discharge permits for its subsidiaries, with validity extending until 2029[164] - The company has implemented a self-monitoring plan in accordance with the latest pollution discharge permit requirements[167] - The company has implemented emergency response plans for environmental incidents and has filed them accordingly[168] Employee Management and Development - The company has established a comprehensive employee care mechanism, including health management and customized insurance plans for different job roles[146] - The company has launched a talent development program, including a new employee training camp and a "Yuheng Talent Program" to enhance employee skills and loyalty[148] - The company has a dual career path system for employees, allowing for advancement in both management and professional tracks[150] - The company has implemented a health and wellness program, including annual health check-ups and psychological support services for employees[147] - The total number of employees at the end of the reporting period is 2,703, with 64 in the parent company and 2,639 in major subsidiaries[143] Legal and Regulatory Matters - The company is involved in a lawsuit regarding the sale of a 42.12% stake in Guangzhou Yuheng Biotechnology Co., with a claim of 117.6 million yuan for unpaid transfer fees[189] - The company received a civil judgment from the Beijing High Court, which upheld the original ruling, dismissing the appeal[190] - The company has received warning letters from the China Securities Regulatory Commission for issues related to compliance, with specific actions taken to address these concerns[191]

誉衡药业（002437）公告，2025年第一季度营收为5.51亿元，同比下降7.06%；净利润为6025.23万元， 同比增长15.24%。 ...

Core Viewpoint - The company has decided to repurchase and cancel a total of 1,653,000 restricted stocks from 8 former incentive recipients, which accounts for 0.07% of the company's total share capital prior to the repurchase [2][9]. Summary by Sections Repurchase Details - The repurchase of the restricted stocks was conducted using the company's own funds, with a total expenditure of RMB 2,094,062.96, calculated at a repurchase price of 1.25 RMB per share plus the interest from the People's Bank of China [2][10][11]. - The repurchase and cancellation procedures have been completed as of the announcement date, with the necessary formalities fulfilled at the Shenzhen branch of China Securities Depository and Clearing Co., Ltd [2][12]. Background of the Repurchase - The incentive recipients, including Li Xiaochuan and Yin Jiao, no longer meet the criteria set forth in the 2024 Restricted Stock Incentive Plan due to their departure from the company [3][9]. - The decision to cancel their incentive qualifications and repurchase the stocks was approved during the board and shareholder meetings held on January 21 and February 6, 2025 [3][9]. Approval Process - The company followed the required approval process for the 2024 Restricted Stock Incentive Plan, which included multiple board meetings and public announcements regarding the incentive recipients [4][5][6]. - Legal opinions were obtained from Beijing Zhide Law Firm regarding the repurchase and cancellation of the restricted stocks [6][9]. Impact on Company - The repurchase of the restricted stocks will not affect the company's stock distribution in a way that violates listing requirements, nor will it have a significant impact on the company's operational performance [12].

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-026 哈尔滨誉衡药业股份有限公司 关于 2024 年限制性股票激励计划部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1、本次回购注销的 8 名激励对象限制性股票共计 1,653,000 股，占回购注销 前哈尔滨誉衡药业股份有限公司（以下简称"公司"）总股本的 0.07%。 2、本次回购限制性股票的资金来源为公司自有资金，回购价格为授予价格 1.25 元/股加上中国人民银行同期存款利息之和，用于本次回购的资金总额为人 民币 2,094,062.96 元。 3、截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公 司办理完成上述限制性股票的回购注销手续。 公司 2024 年限制性股票激励计划首次授予及预留授予的激励对象李晓川、 尹娇等 8 名激励对象已离职，已不符合《2024 年限制性股票激励计划（草案）》 （以下简称"《激励计划》"）有关激励对象的规定，经公司 2025 年 1 月 21 日 召开的第六届董事会第十 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002437 证券简称：誉衡药业 公告编号：2025-024 哈尔滨誉衡药业股份有限公司 关于诉讼进展暨收到二审《民事判决书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、案件所处的诉讼阶段：二审终审判决； 2、上市公司所处的当事人地位：一审原告，二审被上诉人； 3、涉案金额：股权转让款117,600, 000元及违约金（以117,600,000元为基数，按照日万分之三的标准， 自2024年1月1日起计算至实际给付之日止）； 4、对公司损益产生的影响：本判决为终审判决。本诉讼对公司本期或期后利润的具体影响需结合后续 执行情况而定。 一、本次诉讼的基本情况 因青岛普晟普利企业管理中心（有限合伙）（以下简称"普晟普利"）未能在约定时间内向公司支付购买 广州誉衡生物科技有限公司42.12%股权的11,760万元股权转让款，为维护公司及股东的合法权益，公司 于2024年4月9日委托北京浩天律师事务所向法院提交了民事起诉状等立案材料。2024年4月18日，公司 获悉法院已受理该案件。具 ...

特别提示： 数量为 32,307,224 股，占本次注销前公司总股本的 1.42%。 公司办理完毕上述回购股份的注销手续。 一、回购股份的实施情况 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》（以下简称"《回购指引》"）等有关规定，公司第六届 董事会第十七次会议、2024 年第三次临时股东大会审议通过了股份回购方案。 同意公司使用自有资金或自筹资金通过集中竞价交易方式回购公司已发行的部 分人民币普通股（A 股），回购的股份将全部予以注销并减少公司注册资本，本 次回购资金总额不低于人民币 5,000 万元（含本数）且不超过人民币 10,000 万元 （含本数），回购股份的价格不超过人民币 3.00 元/股（含本数）。具体内容详 见公司 2024 年 10 月 22 日披露于《证券时报》、《中国证券报》及巨潮资讯网 http://www.cninfo.com.cn（以下简称"指定媒体"）的《关于以集中竞价交易方 式回购公司股份方案的公告》。 本次实际回购时间区间为 2025 年 3 月 10 日至 2025 年 3 月 13 日，上述期 间内，公司累计回购股份数量 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-025 哈尔滨誉衡药业股份有限公司 关于回购股份注销完成暨股份变动的公告 二、回购股份的注销情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、哈尔滨誉衡药业股份有限公司（以下简称"公司"）本次注销的股份 数量为 32,307,224 股，占本次注销前公司总股本的 1.42%。 2、公司已于 2025 年 3 月 28 日在中国证券登记结算有限责任公司深圳分 公司办理完毕上述回购股份的注销手续。 一、回购股份的实施情况 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》（以下简称"《回购指引》"）等有关规定，公司第六届 董事会第十七次会议、2024 年第三次临时股东大会审议通过了股份回购方案。 同意公司使用自有资金或自筹资金通过集中竞价交易方式回购公司已发行的部 分人民币普通股（A 股），回购的股份将全部予以注销并减少公司注册资本，本 次回购资金总额不低于人民币 5,000 万元（含本数）且不超过人民币 10, ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-024 哈尔滨誉衡药业股份有限公司 关于诉讼进展暨收到二审《民事判决书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：二审终审判决； 2、上市公司所处的当事人地位：一审原告，二审被上诉人； 3、涉案金额：股权转让款 117,600, 000 元及违约金（以 117,600,000 元为基 数，按照日万分之三的标准，自 2024 年 1 月 1 日起计算至实际给付之日止）； 4、对公司损益产生的影响：本判决为终审判决。本诉讼对公司本期或期后 利润的具体影响需结合后续执行情况而定。 一、本次诉讼的基本情况 因青岛普晟普利企业管理中心（有限合伙）（以下简称"普晟普利"）未能 在约定时间内向公司支付购买广州誉衡生物科技有限公司 42.12%股权的 11,760 万元股权转让款，为维护公司及股东的合法权益，公司于 2024 年 4 月 9 日委托 北京浩天律师事务所向法院提交了民事起诉状等立案材料。2024 年 4 月 18 日， 公 ...